CCR5 Inhibition in Critical COVID-19 Patients Decreases Inflammatory Cytokines, Increases CD8 T-Cells, and Decreases SARS-CoV2 RNA in Plasma by Day 14

Since the initial cases of COVID-19 were reported from Wuhan, China in December 2019 (Huang et al., 2020), SARS-CoV-2 has emerged as a global pandemic with an ever increasing number of severe and critical cases requiring invasive external ventilation that threatens to overwhelm health care systems (World Health Organization, 2020). While it remains unclear why COVID-19 patients experience a spectrum of clinical outcomes ranging from asymptomatic to severe disease, features of critical COVID-19 include rampant inflammation and cytokine release syndrome (CRS) leading to ARDS (Mehta et al., 2020, Qin et al., 2020).

Source: International Journal of Infectious Diseases - November 9, 2020 Category: Infectious Diseases Authors: Bruce K. Patterson, Harish Seethamraju, Kush Dhody, Michael J. Corley, Kazem Kazempour, Jay Lalezari, Alina P.S. Pang, Christopher Sugai, Eisa Mahyari, Edgar B. Francisco, Amruta Pise, Hallison Rodrigues, Helen L. Wu, Gabriela M. Webb, Byung S. Park, Scot Source Type: research